Navigation Links
CureHIV Reaches Out to Bill and Melinda Gates to Fund LiSAVIOR
Date:3/28/2008

HILTON HEAD ISLAND, S.C., March 28 /PRNewswire/ -- Dr. Roger Kenneth Hershline PhD MD, the CEO of Global Humanceuticals, Inc. and founder and chairman of the not-for-profit public charity CureHIV.us, announces today that he is reaching out to Bill and Melinda Gates for funding from their Grand Challenges in Global Health initiative. The monies will be used to begin clinical studies of a new drug and treatment method, LiSAVIOR.

This unique new drug is also known as compound NIAID #11039 and has received a patent from the United States with patent number: 6,821,958 on November 23, 2004. Also, the World International Patent Organization published the International Application Number as PCT/US2005/039528 on November 5, 2006.

Dr. Hershline hosted Session V at the World Aids Day Conference China from December 1 to December 3, 2006, to initially present LiSAVIOR.

The proposed roadblock to cure HIV is that current drug and vaccination treatments do not treat the growth of HIV in the gastrointestinal tract. HIV virus multiplies and mutates in the gastrointestinal tract and then is reabsorbed into the blood. This process is known to occur when HIV infection results from the use of contaminated needles or during sexual intercourse. The gastrointestinal tract is comprised of the mouth and its structures, the pharynx, the esophagus, the stomach, the small intestines, the large intestines and the anus.

The proposed solution to overcome this roadblock is the oral clinical use of LiSAVIOR, a drug that is an early stage HIV life cycle inhibitor. LiSAVIOR blocks not only viral entry into cells but also cell-to-cell transfer of the virus. LiSAVIOR is proposed to be used alone or with any known HIV drug and vaccine therapy.

Pre-clinical efficacy testing of LiSAVIOR has shown that the effective concentration of LiSAVIOR is found to be equivalent to diluting a 1% solution of LiSAVIOR one million times. LiSAVIOR is a dry, palatable, non-toxic powder that is stable at room temperature and humidity.

"I am thinking in terms of problem solving. Traditional commercial drug design and projects funding from the NIH has completely ignored this approach to date," stated Dr. Hershline. "I think we have to talk in terms of a cure for HIV. I want to cure HIV and that is why my foundation is called CureHIV.us," concluded Dr. Hershline.

Dr. Hershline is hopeful that Bill and Melinda Gates and their Global Initiative funding looks into the work and progress that he has made towards solving this problem and fills the gap in funding.

Dr. Hershline has a doctorate degree in drug design and a medical degree. Pre-clinical development of LiSAVIOR has been twenty years in the making. Despite the critical need for such a unique and potentially life saving invention, LiSAVIOR remains completely un-funded.

Interested parties can contact Dr. Roger Kenneth Hershline PhD MD thru CureHIV.us Headquarters by email: Roger@CureHIV.us, mail P.O. Box 23467, Hilton Head Is., SC, 29925, by fax: +1-843-342-5924, phone: +1-843-342-5900. Direct to Dr. Hershline: +1-843-683-3683.

Web site: http://www.curehiv.us


'/>"/>
SOURCE CureHIV.us
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cancer Pioneer Reaches Key Agreement on Colon Cancer Drug OncoVAX(R)
2. CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema
3. Arizona Heart Hospital Reaches Settlement Regarding Clinical Research Matter
4. Enrollment Reaches 110 Patients in Investigator Initiated, Randomized Trial of OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM)
5. Gates Foundation Seeks Proposals for Innovative Global Health Research
6. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
7. Study of Pathwork Diagnostics Tissue of Origin Test Published in the Journal of Molecular Diagnostics: Investigates Test Reproducibility in Multiple Labs to Determine Primary Tumor in Cancer Cases
8. Researcher Investigates Disparities in Doctor-Patient Information Exchange During Clinical Trial Offers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
(Date:4/19/2017)... , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: ... Burton & Co. Healthcare Investor Conference 2017 at the Sheraton Hotel ... Wright , Chief Executive Officer of the Company is scheduled to ... Richard Bear and the Chairman of the Board, ... ...
(Date:4/19/2017)... MOUNTAIN VIEW, Calif. , April 19, 2017 /PRNewswire/ ... that it will release financial results for the first ... May 3, 2017.  The Company,s management team will host ... / 5:30 p.m. ET. Investors interested in ... dialing (844) 707-0665 for domestic callers or (703) 326-3030 ...
Breaking Medicine Technology:
(Date:4/24/2017)... (PRWEB) , ... April 24, 2017 , ... The bar ... glitterati, those unreal icons inhabiting the rarified air of pop and film stardom.(1) Not ... and anyone snapping pictures: the smile. Grins now run the gamut from being encrusted ...
(Date:4/24/2017)... ... 24, 2017 , ... Sean Fay is the undisputed king of the infomercial. ... and the George Foreman Grill (which sold more than 100 million units worldwide), he ... years. , Now, due to changes in the broadcast media landscape, the once ever-present ...
(Date:4/24/2017)... ... April 24, 2017 , ... ALP ... food supplements, announced its popular products are now available for purchase on StackedNutrition.com, ... prioritizes the use of premium natural ingredients in making all of its products. ...
(Date:4/24/2017)... ... April 24, 2017 , ... Salus Telehealth, ... the company’s VideoMedicine mobile platform has launched Quick Care, a new service offering ... Quick Care provides patients with the option to request and begin a consultation ...
(Date:4/24/2017)... CA (PRWEB) , ... April 24, 2017 , ... ... brain tumors are expected to be diagnosed globally; approximately 25,000 of them will ... are anticipating greater use of this type of healthcare model in the diagnosis ...
Breaking Medicine News(10 mins):